ANTIMICROBIAL PEPTIDES ARE TARGETS FOR BACTERIAL ADP-RIBOSYLTRANSFERASE ENZYMES

Background: Human α-defensins (HNPs 1-3) are small cationic, amphipatic peptides with microbicidal activities. HNP-1 is the physiological target of ART1, an arginine (Arg) specific eucaryotic ribosyltransferase enzyme1. Mono ADP-ribosylation of Arg14 of HNP-1 modulates its biological activities2. Bacterial exotoxins like Cholera Toxin (CT) by Vibrio cholerae, Heat Labile Enterotoxin (LT1) by Escherichia coli and Exoenzyme S (ExoS) by Pseudomonas aeruginosa are arginine ADP-ribosyltransferase enzymes that alter cell functions by modifying protein targets. Objectives: 1. Evaluate the ADP ribosylation of HNP-1 by CT, LT1 and ExoS. 2. Purify modified peptides and identify the ADP-ribosylated Arg. Methods: ADP-ribosylation of HNP-1 will be evaluated with biotinilated NAD by western blot. Purification of modified peptides will be performed by reverse phase HPLC. Identification of modification will be performed by Maldi-Toff analysis. Results: 1. CT and LT1 are effective in ADP-ribosylating HNP-1 as equal as the well known activity of ART1. On the other hand ExoS does not recognize HNP-1 as substrate. 2. Ongoing experiments are purifications and characterization of modified peptides by reverse-phase HPLC and Maldi-Toff analysis. Conclusions: 1. The different ADP-ribosylating activities displayed by CT, LT1 and ExoS on HNP-1 might be explained with differences in microbial pathogenesis, as the toxins released by V. cholerae and E. coli are involved in the early stages of infections, during the interactions with surface epithelial cells, while ExoS by P. aeruginosa is active during blood dissemination, when the pathogen has already overcome epithelial barrier. References: 1 Balducci et al., 1999, Am J Respir Cell Mol Biol, 21, 337-46 2 Paone et al., 2006, J Biol Chem, 281, 17054-6

The factor H binding protein of Neisseria meningitidis interacts with xenosiderophores in vitro.

The factor H binding protein (fHbp) is a key virulence factor of Neisseria meningitidis that confers to the bacterium the ability to resist killing by human serum. The determination of its three-dimensional structure revealed that the carboxyl terminus of the protein folds into an eight-stranded ߠbarrel. The structural similarity of this part of the protein to lipocalins provided the rationale for exploring the ability of fHbp to bind siderophores. We found that fHbp was able to bind in vitro siderophores belonging to the cathecolate family and mapped the interaction site by nuclear magnetic resonance. Our results indicated that the enterobactin binding site was distinct from the site involved in binding to human factor H and stimulates new hypotheses about possible multiple activities of fHbp.Full Tex

Exploring host-pathogen interactions through genome wide protein microarray analysis

During bacterial pathogenesis extensive contacts between the human and the bacterial extracellular proteomes take place. The identification of novel host-pathogen interactions by standard methods using a case-by-case approach is laborious and time consuming. To overcome this limitation, we took advantage of large libraries of human and bacterial recombinant proteins. We applied a large-scale protein microarray-based screening on two important human pathogens using two different approaches: (I) 75 human extracellular proteins were tested on 159 spotted Staphylococcus aureus recombinant proteins and (II) Neisseria meningitidis adhesin (NadA), an important vaccine component against serogroup B meningococcus, was screened against ∼2300 spotted human recombinant proteins. The approach presented here allowed the identification of the interaction between the S. aureus immune evasion protein FLIPr (formyl-peptide receptor like-1 inhibitory protein) and the human complement component C1q, key players of the offense-defense fighting; and of the interaction between meningococcal NadA and human LOX-1 (low-density oxidized lipoprotein receptor), an endothelial receptor. The novel interactions between bacterial and human extracellular proteins here presented might provide a better understanding of the molecular events underlying S. aureus and N. meningitidis pathogenesis

Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic

This study aimed to describe the change in surgical practice and the impact of SARS-CoV-2 on mortality after surgical resection of colorectal cancer during the initial phases of the SARS-CoV-2 pandemic

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

Background: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on postoperative recovery needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. This study reports 30-day mortality and pulmonary complication rates in patients with perioperative SARS-CoV-2 infection. Methods: This international, multicentre, cohort study at 235 hospitals in 24 countries included all patients undergoing surgery who had SARS-CoV-2 infection confirmed within 7 days before or 30 days after surgery. The primary outcome measure was 30-day postoperative mortality and was assessed in all enrolled patients. The main secondary outcome measure was pulmonary complications, defined as pneumonia, acute respiratory distress syndrome, or unexpected postoperative ventilation. Findings: This analysis includes 1128 patients who had surgery between Jan 1 and March 31, 2020, of whom 835 (74·0%) had emergency surgery and 280 (24·8%) had elective surgery. SARS-CoV-2 infection was confirmed preoperatively in 294 (26·1%) patients. 30-day mortality was 23·8% (268 of 1128). Pulmonary complications occurred in 577 (51·2%) of 1128 patients; 30-day mortality in these patients was 38·0% (219 of 577), accounting for 81·7% (219 of 268) of all deaths. In adjusted analyses, 30-day mortality was associated with male sex (odds ratio 1·75 [95% CI 1·28–2·40], p\textless0·0001), age 70 years or older versus younger than 70 years (2·30 [1·65–3·22], p\textless0·0001), American Society of Anesthesiologists grades 3–5 versus grades 1–2 (2·35 [1·57–3·53], p\textless0·0001), malignant versus benign or obstetric diagnosis (1·55 [1·01–2·39], p=0·046), emergency versus elective surgery (1·67 [1·06–2·63], p=0·026), and major versus minor surgery (1·52 [1·01–2·31], p=0·047). Interpretation: Postoperative pulmonary complications occur in half of patients with perioperative SARS-CoV-2 infection and are associated with high mortality. Thresholds for surgery during the COVID-19 pandemic should be higher than during normal practice, particularly in men aged 70 years and older. Consideration should be given for postponing non-urgent procedures and promoting non-operative treatment to delay or avoid the need for surgery. Funding: National Institute for Health Research (NIHR), Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, NIHR Academy, Sarcoma UK, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research

D-specific dehalogenases, a review

Bacterial dehalogenases cleave carbon-halogen bonds with different stereo-configurations. Rhizobium sp. RC1 produces a D-haloalkanoic-specific dehalogenase (DehD) that can cleave the carbon-halogen bond of halogenated organic pollutants. The sequence identity for DehD and HadD from Pseudomonas putida AJ1 is 27%, and 20 amino acid residues are highly conserved in these two enzymes. Therefore, DehD and HadD may have active sites that contain the same charged catalytic residues. The activity of DehD rapidly increases with increasing pH and is optimum at pH 9.5. It also has lower Km values and higher kcat values for various substrates than do other D-specific dehalogenases. Because DehD catalyzes the hydrolytic dehalogenation of D-haloalkanoic acids with inversion around the chiral carbon, it has potential industrial applications. Site-directed mutagenesis of DehD can be exploited for industrial production of chemicals, pharmaceutical and medical applications, and in environmental remediation

Arginine-specific mono ADP-ribosylation in vitro of antimicrobial peptides by ADP-ribosylating toxins

Among the several toxins used by pathogenic bacteria to target eukaryotic host cells, proteins that exert ADP-ribosylation activity represent a large and studied family of dangerous and potentially lethal toxins. These proteins alter cell physiology catalyzing the transfer of the ADP-ribose unit from NAD to cellular proteins involved in key metabolic pathways. In the present study, we tested the capability of four of these toxins, to ADP-ribosylate α- and β- defensins. Cholera toxin (CT) from Vibrio cholerae and heat labile enterotoxin (LT) from Escherichia coli both modified the human α-defensin (HNP-1) and β- defensin-1 (HBD1), as efficiently as the mammalian mono-ADP-ribosyltransferase-1. Pseudomonas aeruginosa exoenzyme S was inactive on both HNP-1 and HBD1. Neisseria meningitidis NarE poorly recognized HNP-1 as a substrate but it was completely inactive on HBD1. On the other hand, HNP-1 strongly influenced NarE inhibiting its transferase activity while enhancing auto-ADP-ribosylation. We conclude that only some arginine-specific ADP-ribosylating toxins recognize defensins as substrates in vitro. Modifications that alter the biological activities of antimicrobial peptides may be relevant for the innate immune response. In particular, ADP-ribosylation of antimicrobial peptides may represent a novel escape mechanism adopted by pathogens to facilitate colonization of host tissue